This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

  • Clinicaltrials.gov identifier

    NCT03656718

  • Recruitment Status

    Recruiting

  • First Posted

    September 4, 2018

  • Last update posted

    September 30, 2021

Study Description

Brief summary:

The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: - non-small cell lung cancer (NSCLC) - renal cell carcinoma (RCC) - unresectable or metastatic melanoma - hepatocellular carcinoma (HCC) - microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H/dMMR CRC) - in Part B, other solid tumors may be considered at the discretion of the Clinical Trial Physician - In addition to the above tumors, Part E will also include participants with metastatic urothelial carcinoma (mUC).

  • Condition or Disease:Neoplasms by Site
  • Intervention/Treatment: Biological: nivolumab
    Drug: rHuPH20
    Biological: nivolumab
  • Phase: Phase 1/Phase 2

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 170 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
  • Actual Study Start Date: October 2018
  • Estimated Primary Completion Date: October 2022
  • Estimated Study Completion Date: July 2025

Arms and interventions

Arm Intervention/treatment
Experimental: Part A, Group 1: nivolumab (dose 1) + rHuPH20
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Drug: rHuPH20
Specified dose on specified days Permeation enhancer

Biological: nivolumab
(IV) Specified Dose on Specified Days
Experimental: Part B, Group 2: nivolumab (dose 1)
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Biological: nivolumab
(IV) Specified Dose on Specified Days
Experimental: Part B, Group 3: nivolumab (dose 2) + rHuPH20
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Drug: rHuPH20
Specified dose on specified days Permeation enhancer

Biological: nivolumab
(IV) Specified Dose on Specified Days
Experimental: Part B, Group 4: nivolumab (dose 2)
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Biological: nivolumab
(IV) Specified Dose on Specified Days
Experimental: Part C: nivolumab (dose 3) + rHuPH20
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Drug: rHuPH20
Specified dose on specified days Permeation enhancer
Experimental: Part D, Group 5: nivolumab (dose 3) + rHuPH20
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Drug: rHuPH20
Specified dose on specified days Permeation enhancer
Experimental: Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20
Biological: nivolumab
(Subcutaneous) Specified dose on specified days

Drug: rHuPH20
Specified dose on specified days Permeation enhancer

Outcome Measures

  • Primary Outcome Measures: 1. Maximum observed serum concentration (Cmax) [ Time Frame: Approximately 4 years ]
  • 2. Time of maximum observed serum concentration (Tmax) [ Time Frame: Approximately 4 years ]
  • 3. Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)] [ Time Frame: Approximately 4 years ]
  • 4. Observed serum concentration at the end of a dosing interval (Ctau) [ Time Frame: Approximately 4 years ]
  • 5. Trough observed serum nivolumab concentration (Ctrough) [ Time Frame: Approximately 4 years ]
  • Secondary Outcome Measures: 1. Incidence of Serious Adverse Events (SAEs) [ Time Frame: Approximately 4 years ]
  • 2. Incidence of Treatment Related SAEs (TRSAEs) [ Time Frame: Approximately 4 years ]
  • 3. Incidence of death [ Time Frame: Approximately 4 years ]
  • 4. Incidence of clinically significant changes in clinical laboratory values: Hematology tests [ Time Frame: Approximately 4 years ]
  • 5. Incidence of Adverse Events (AEs) [ Time Frame: Approximately 4 years ]
  • 6. Incidence of AEs leading to deaths [ Time Frame: Approximately 4 years ]
  • 7. Incidence of AEs leading to laboratory abnormalities [ Time Frame: Approximately 4 years ]
  • 8. Incidence of AEs leading to discontinuation [ Time Frame: Approximately 4 years ]
  • 9. Incidence of Treatment Related AEs (TRAEs) [ Time Frame: Approximately 4 years ]
  • 10. Incidence of TRAEs leading to laboratory abnormalities [ Time Frame: Approximately 4 years ]
  • 11. Incidence of TRAEs leading to discontinuation [ Time Frame: Approximately 4 years ]
  • 12. Incidence of TRAEs leading to deaths [ Time Frame: Approximately 4 years ]
  • 13. Incidence of clinically significant changes in clinical laboratory values: Chemistry tests [ Time Frame: Approximately 4 years ]
  • 14. Incidence of clinically significant changes in clinical laboratory values: Serology tests [ Time Frame: Approximately 4 years ]
  • 15. Number of Clinically Significant Changes in Lab Assessment of: Blood Serum [ Time Frame: Approximately 4 years ]
  • 16. Number of Clinically Significant Changes in Lab Assessment of: Urine [ Time Frame: Approximately 4 years ]
  • 17. Incidence of AEs in the broad standardized MedDRA queries (SMQ) of Anaphylactic Reaction [ Time Frame: Approximately 4 years ]
  • 18. Incidence of events within the hypersensitivity/infusion reaction select AE category [ Time Frame: Approximately 4 years ]
  • 19. Incidence of anti-nivolumab antibodies [ Time Frame: Approximately 4 years ]
  • 20. Incidence of neutralizing antibodies [ Time Frame: Approximately 4 years ]

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of advanced (metastatic and/or unresectable) solid tumors of one of the following tumor types: 1. Metastatic squamous or non-squamous NSCLC 2. RCC, advanced or metastatic 3. Melanoma 4. HCC 5. CRC, metastatic (MSI-H or dMMR) 6. In Part B, other solid tumor types may be considered at the discretion of the Medical Monitor 7. In Part E, Metastatic urothelial carcinoma - Measurable disease as per RECIST version 1.1 criteria - ECOG performance status of 0 or 1 Exclusion Criteria: - Active brain metastases or leptomeningeal metastases - Ocular melanoma - Active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply

Contacts and Locations

Contacts

Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email ClinicalTrials@bms.com

Contact: First line of the email MUST contain NCT # and Site #.

Locations

United States, Georgia
Winship Cancer Institute.
Atlanta

United States, Maryland
Maryland Oncology Hematology, P.A.
Rockville

United States, Michigan
Karmanos Cancer Institute
Detroit

United States, Minnesota
Local Institution
Minneapolis

United States, North Carolina
Levine Cancer Institute
Charlotte

United States, Oregon
Willamette Valley Cancer Institute And Research Center
Eugene

United States, South Carolina
Greenville Health System
Greenville

United States, Texas
Texas Oncology- Austin Midtown
Austin

United States, Texas
Texas Oncology-Beaumont
Beaumont

United States, Texas
Texas Oncology - Baylor Charles A. Simmons Cancer Center
Dallas

United States, Texas
Uus Oncology
Tyler

Argentina
Local Institution
Caba

Argentina
Local Institution
Caba

Brazil, Rio Grande Do Sul
Local Institution
Porto Alegre

Brazil
Local Institution
Sao Paulo

Chile, Metropolitana
Local Institution
Santiago

Chile
Clinica San Carlos de Apoquindo
Santiago

France
Institut De Cancerologie De L Ouest
Saint Herblain

France
Institut Gustave Roussy
Villejuif

Italy
Istituto Oncologico Veneto IOV
Padova

Italy
Local Institution
Rozzano

Netherlands
Local Institution
Amsterdam

Netherlands
Local Institution
Maastricht

New Zealand, Wellington
Local Institution
Newtown

New Zealand
Local Institution
Dunedin

New Zealand
Local Institution
Tauranga

Poland, Mazowieckie
Local Institution
Warszawa

Spain
Hospital Gral. Univ. Gregorio Maranon
Madrid

Spain
Hospital Universitario Virgen De La Victoria
Malaga

United Kingdom, Glamorgan
Local Institution
Cardiff

United Kingdom
Local Institution
Cambridge

United Kingdom
Local Institution
Leicester

United Kingdom
Local Institution
Liverpool

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators

Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

More Information

  • Responsible Party: Bristol-Myers Squibb
  • ClinicalTrials.gov Identifier: NCT03656718 History of Changes
  • Other Study ID Numbers: CA209-8KX, 2018-001585-42
  • First Posted: September 4, 2018 Key Record Dates
  • Last Update Posted: September 30, 2021
  • Last Verified: September 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Bristol-Myers Squibb: rHuPH20
    Nivolumab
    Subcutaneous
  • Additional relevant MeSH terms: Neoplasms by Site